Venipuncture/Biometric Screeners

Labcorp to acquire BioReference Health clinical, women's health and urology testing assets from OPKO for $722 million. Traders Agency Team The Traders Agency editorial team delivers daily market anal... Follow Traders Agency on Google. Add Traders Agency, LLC as a preferred source so its market analysis shows up more in your Search and AI results. Labcorp and OPKO Health announced on October 15, 2026 that Labcorp has agreed to acquire select assets of BioReference Health, LLC, OPKO's wholly owned laboratory subsidiary, for $722 million in cash at closing, with the price subject to adjustment based on closing business revenues, plus up to an additional $150 million tied to future revenue from BioReference's 4Kscore prostate cancer test, according to a joint press release from the two companies. Deal terms and potential value. The $722 million cash component and the $150 million 4Kscore earnout together put the transaction's maximum potential value at $872 million, as reported by Medical Device Developments. Using the figures disclosed by the companies, its calculation shows the cash payment exceeds the earnout by $572 million ($722 million minus $150 million), or roughly 381% more than the contingent payment ((722 − 150) / 150 x 100). As an interpretation of that arithmetic, the upfront cash represents the bulk of the deal's value, with the earnout functioning as a smaller, performance-linked add-on; it is a comparison of the two disclosed amounts, not a forecast of what will ultimately be paid. Neither company's release specified the revenue thresholds or measurement period required to trigger the full $150 million 4Kscore earnout, nor did they disclose how the base $722 million price might be adjusted up or down based on BioReference's revenue at the time of closing. What Labcorp is acquiring. Labcorp will acquire BioReference's laboratory testing businesses focused on clinical and women's health testing services, urology, and diagnostic services provided to correctional institutions, along with certain operational assets including more than 80 additional patient service centers, per the joint announcement. Also included is BioReference's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision. According to Medical Device Developments, the 4Kscore test secured FDA approval in 2021 after being available as a laboratory-developed test since 2014, and it assesses the probability of finding aggressive prostate cancer in men 45 or older with an age-stratified elevated PSA or a positive nodule on a digital rectal examination. The same outlet reported that OPKO's diagnostics segment generated $74.5 million in revenue in the second quarter, of which the 4Kscore test contributed $6.3 million, though the companies' releases did not break out what share of OPKO's overall diagnostics revenue or earnings the divested BioReference businesses represent, or what remains at OPKO after the deal closes. Rationale from both sides. OPKO Chairman and CEO Phillip Frost framed the sale as a step toward concentrating on drug development, saying, "This transaction will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business," according to the joint release. The statement did not specify how OPKO intends to deploy the cash proceeds, such as through debt reduction, pipeline funding or share repurchases. On Labcorp's side, Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp, said the acquisition "strengthens our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers around the country," according to a PR Newswire version of the announcement. Labcorp expects the acquired business to generate approximately $250 million in revenue in the first year after close, based on its current post-closing forecasts, the companies said. Closing timeline and advisors. The transaction is subject to regulatory approvals and customary closing conditions. The companies said there will be no changes to operations or services and that both will continue to operate independently until closing; neither release specified an expected closing date. According to the joint release, Lazard is serving as Labcorp's financial advisor, with Hogan Lovells Cadwalader US LLP as lead transaction counsel and Parker Poe as real estate counsel. Piper Sandler & Co. is serving as OPKO's exclusive financial advisor, with Greenberg Traurig P.A. as legal counsel. Analyst reaction. According to Yahoo Finance, Evercore ISI analysts said the deal fits Labcorp's strategy of expanding in higher-growth specialty testing, writing that "women's health strengthens the specialty offering, while 4Kscore adds a differentiated asset with an opportunity for broader distribution rather than simply more routine testing volume." William Blair analysts, cited in the same report, called the 4Kscore test a "particularly compelling asset" with opportunity for broader adoption, saying it could help identify patients for further evaluation and avoid unnecessary biopsies. These are the analysts' own characterizations and not independently verified projections. Bottom line. The agreement adds a defined set of clinical, women's health, urology and corrections testing operations plus the 4Kscore prostate test to Labcorp's network, with Labcorp projecting roughly $250 million in first-year revenue from the assets. The companies have not disclosed a closing date, the specific 4Kscore earnout thresholds, or how OPKO plans to use the proceeds, and both releases caution that timing, final purchase price and earnout outcomes remain subject to regulatory approval and other conditions outside either company's control. Related reading. DISCLAIMER: Traders Agency does not offer financial advice. The information provided is for educational purposes only and should not be considered financial advice. Traders Agency is not responsible for any financial losses or consequences resulting from the use of the information provided. Trading carries inherent risks and may not be suitable for all individuals. You are advised to conduct your own research and seek personalized advice before making any investment decisions, recognizing the potential risks and rewards involved. See more from Traders Agency on Google. Make Traders Agency, LLC a preferred source and its market analysis will appear more prominently in your Google Search, Top Stories, and AI results. The Traders Agency editorial team delivers daily market analysis, stock research, and trading education. Its team of analysts covers stocks, options, crypto, commodities, and macroeconomics to help traders make informed decisions. Join the Edge Stop watching. Start winning. 50,000+ traders get its daily brief before the market opens. Free. No spam. Unsubscribe anytime.

Labcorp enters into agreement with OPKO Health to acquire select assets of BioReference Health. Oct 15, 2026, 07:30 ET Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ - Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets, including over 80 additional patient service centers. As part of the agreement, Labcorp will also acquire BioReference Health's proprietary 4Kscore(R) Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision, making this important test more broadly available to patients across the country. When complete, the transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, including a broad specialty testing menu, convenient patient service center network and robust data analytics and digital tools. "This acquisition strengthens our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers around the country," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By expanding our clinical, women's health, urology and corrections testing capabilities and broadening access to innovative diagnostics such as the FDA-approved 4Kscore Test, we can help providers make more informed decisions, improve patient care and increase access to the comprehensive laboratory services people need to live healthier lives." "This transaction will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. "Labcorp's national scale and capabilities will broaden patient and provider access to BioReference's 4Kscore Test to many more patients across the country. We believe this transaction is an important catalyst to further unlock additional value for our shareholders." The purchase price for the transaction is $722 million in cash at closing, subject to an upward or downward adjustment (if any) based on closing business revenues, and up to an additional $150 million in an earnout based on revenue from the 4Kscore Test. Labcorp expects the business revenue to be approximately $250 million in the first year after close, based on Labcorp's current post-closing forecasts. This transaction is subject to regulatory approvals and customary closing conditions. Until the transaction closes, there will be no changes to operations or services, and both companies will continue to operate independently. Lazard is serving as Labcorp's financial advisor, Hogan Lovells Cadwalader US LLP is serving as lead transaction counsel and Parker Poe is serving as real estate counsel. Piper Sandler & Co. is serving as OPKO's exclusive financial advisor, and Greenberg Traurig P.A. is serving as legal counsel. About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com. About OPKO OPKO Health, Inc. (Nasdaq: OPK) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements with respect to (a) the anticipated impact of the transaction including expanding access to comprehensive, high-quality laboratory services, (b) increased access to testing services and expanded testing capabilities including with respect to the 4Kscore Test, (c) anticipated timing to closing, final purchase price, post-closing revenue, and earnout for the 4Kscore Test, (d) other anticipated potential benefits of the acquisition to Labcorp and OPKO Health, and (e) required regulatory approvals and customary closing conditions. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the control of Labcorp or OPKO Health. These factors, in some cases, have affected and in the future (together with other factors) could affect the ability of Labcorp or OKPO Health to implement its respective business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. Neither Labcorp nor OPKO Health has any obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in each of Labcorp's and OPKO Health's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the headings RISK FACTORS and MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, and in each of Labcorp's and OPKO Health's other filings with the SEC. SOURCE Labcorp Holdings Inc